section,entity_id,entity_name,entity_name_en,entity_type,category,attribute_path,value,source_file
BONE_001,BONE_001,骨质疏松症,,骨代谢疾病,骨代谢疾病,risk_factors.potentially_modifiable.hormonal_factors,早绝经（<45岁）; 晚初潮（>15岁）; 性腺功能减退; 不孕或少孕,BONE_001.csv
NUTRI_003,NUTRI_003,维生素D缺乏症,,营养代谢疾病,营养代谢疾病,risk_factors.physiological,老年; 妊娠哺乳期; 深色皮肤,NUTRI_003.csv
REPRO_001,REPRO_001,多囊卵巢综合征,,生殖内分泌疾病,生殖内分泌疾病,clinical_features.reproductive_manifestations.infertility.prevalence,75%的PCOS患者存在不孕,REPRO_001.csv
REPRO_001,REPRO_001,多囊卵巢综合征,,生殖内分泌疾病,生殖内分泌疾病,clinical_features.reproductive_manifestations.infertility.pregnancy_complications,流产率增加; 妊娠期糖尿病; 子痫前期,REPRO_001.csv
REPRO_001,REPRO_001,多囊卵巢综合征,,生殖内分泌疾病,生殖内分泌疾病,treatment_approach.pharmacological_treatment.hormonal_therapy.combined_ocs.selection,含抗雄激素作用的孕激素,REPRO_001.csv
REPRO_003,REPRO_003,卵巢早衰,,生殖内分泌疾病,生殖内分泌疾病,diagnostic_criteria.clinical_definition.exclusion,排除妊娠和其他闭经原因,REPRO_003.csv
REPRO_003,REPRO_003,卵巢早衰,,生殖内分泌疾病,生殖内分泌疾病,management_approach.fertility_preservation.spontaneous_pregnancy,10%患者可能自然受孕,REPRO_003.csv
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.additional_endocrine_features.gonadal_dysfunction.manifestations,原发性性腺功能减退; 青春期发育延迟; 不孕不育; 闭经,RHEUM_007.csv
RHEUM_007,RHEUM_007,多腺体自身免疫综合征I型 (APS-1),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement.gonadal.estrogen_progesterone,女性雌孕激素替代,RHEUM_007.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,clinical_manifestations.associated_conditions.primary_hypogonadism.manifestations,闭经，不孕; 性欲减退; 骨质疏松; 潮热,RHEUM_008.csv
RHEUM_008,RHEUM_008,多腺体自身免疫综合征II型 (APS-2),,自身免疫性多腺体疾病,自身免疫性多腺体疾病,treatment.hormone_replacement_therapy.gonadal_replacement.female.progestin,孕激素周期治疗,RHEUM_008.csv
RHEUM_009,RHEUM_009,痛风,,晶体性关节病,晶体性关节病,treatment.special_situations.pregnancy,避免大多数降尿酸药物,RHEUM_009.csv
cardiovascular_diseases,CVD_004,心房颤动,,Disease,心血管疾病,treatment.long_term_management.anticoagulation.contraindications,活动性出血; 严重肝功能不全; 妊娠,cardiovascular_diseases.csv
cerebrovascular_diseases,NEURO_003,急性炎症性脱髓鞘性多发性神经病变,,Disease,神经病变,etiology.other_triggers,疫苗接种; 手术; 外伤; 妊娠; 恶性肿瘤,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_001,1型糖尿病,,Disease,自身免疫性内分泌疾病,prognosis.pregnancy_outcomes,孕前血糖控制良好可获得正常妊娠结局,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.hormone_replacement.indications,显性甲减（TSH>10 mIU/L）; 亚临床甲减伴症状; 妊娠期亚临床甲减; 甲状腺肿大明显,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.hormone_replacement.levothyroxine.pregnancy_dose,孕期需要量增加25-50%,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.hormone_replacement.treatment_targets.pregnancy,孕早期TSH<2.5 mIU/L,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.monitoring.frequency.pregnancy,每4-6周监测,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.special_considerations.pregnancy.preconception,TSH优化至<2.5 mIU/L,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.special_considerations.pregnancy.monitoring,每4-6周检测TSH,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,treatment.special_considerations.pregnancy.dose_adjustment,及时调整L-T4剂量,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_002,桥本甲状腺炎,,Disease,自身免疫性内分泌疾病,complications.reproductive,月经异常; 不孕症; 妊娠不良结局,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_003,艾迪生病,,Disease,自身免疫性内分泌疾病,prognosis.pregnancy,需要专科管理，预后良好,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_004,系统性红斑狼疮,,Disease,系统性风湿病,clinical_manifestations.endocrine_associations.reproductive_dysfunction,月经异常; 性腺功能减退; 不孕症,cerebrovascular_diseases.csv
cerebrovascular_diseases,RHEUM_004,系统性红斑狼疮,,Disease,系统性风湿病,treatment.supportive_care.reproductive_health,避孕咨询，妊娠管理,cerebrovascular_diseases.csv
comorbidity_patterns,PATTERN_004,PCOS-代谢综合征复合体,,,,management_strategy.reproductive_management,来曲唑促排卵(生育需求); 复合口服避孕药(无生育需求); 螺内酯抗雄激素治疗,comorbidity_patterns.csv
entities.adrenal_entities,ADR_005,肾上腺偶发瘤,,disease,肾上腺疾病,hormonal_evaluation.conditional_test,醛固酮/肾素比值(高血压或低钾); DHEA-S(女性男性化); 17-羟孕酮(年轻患者),entities_adrenal_entities.csv
entities.diabetes_complications,DM_COMP_001,糖尿病性视网膜病变,,complication,糖尿病微血管并发症,risk_factors.modifiable,血糖控制不佳; 高血压; 血脂异常; 吸烟; 妊娠,entities_diabetes_complications.csv
entities.diabetes_complications,DM_COMP_001,糖尿病性视网膜病变,,complication,糖尿病微血管并发症,screening_guidelines.pregnancy,妊娠前和每个三个月筛查,entities_diabetes_complications.csv
entities.diabetes_entities,DM_001,2型糖尿病,,disease,代谢性疾病,diagnosis.diagnostic_criteria.hba1c.limitations,某些血红蛋白病; 肾病晚期; 妊娠期不适用,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,name_en,Gestational Diabetes Mellitus,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,icd10,O24.4,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,description,妊娠期间首次发现或发病的糖耐量异常,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,epidemiology.global_prevalence,1-14%（因诊断标准而异）,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,epidemiology.china_prevalence,17.5%（2019年全国调查）,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,epidemiology.trend,发病率持续上升,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,epidemiology.risk_factors_prevalence,高龄妊娠、肥胖增加,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,pathophysiology.hormonal_changes.insulin_resistance,妊娠期胰岛素敏感性下降50-60%,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,pathophysiology.hormonal_changes.placental_hormones,人胎盘泌乳素（hPL）; 雌激素; 孕激素; 皮质醇; 胎盘胰岛素酶,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,pathophysiology.hormonal_changes.progressive_nature,孕周增加胰岛素抵抗加重,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,pathophysiology.beta_cell_adaptation.normal_pregnancy,β细胞代偿性增生和功能增强,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,pathophysiology.beta_cell_adaptation.gdm_pathogenesis,β细胞代偿不足导致高血糖,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,risk_factors.major_risk_factors,年龄≥35岁; 孕前BMI≥24 kg/m²; 糖尿病家族史（一级亲属）; 既往GDM史; 既往不良孕产史（巨大儿、死胎、多胎畸形）; 多囊卵巢综合征; 孕期体重增加过多,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,risk_factors.minor_risk_factors,高血压; 高龄初产; 反复流产史; 羊水过多,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.screening_timing.first_screening,孕24-28周（最佳时间）,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.screening_timing.early_screening.indications,高危因素存在,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.screening_timing.early_screening.timing,孕早期（<20周）,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.screening_timing.early_screening.method,空腹血糖或HbA1c,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.standard_protocol.preparation,正常饮食3天，空腹8-14小时,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.standard_protocol.glucose_load,75g无水葡萄糖溶于300ml水中,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.standard_protocol.sampling_times,0分钟; 60分钟; 120分钟,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.iadpsg_criteria.fasting,≥5.1 mmol/L (92 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.iadpsg_criteria.1_hour,≥10.0 mmol/L (180 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.iadpsg_criteria.2_hour,≥8.5 mmol/L (153 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.75g_ogtt.iadpsg_criteria.diagnostic_threshold,任何一项异常即可诊断,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.alternative_screening.50g_gct,50g葡萄糖激发试验（筛查用）,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,screening_diagnosis.diagnostic_tests.alternative_screening.threshold,1小时血糖≥7.8 mmol/L需进一步OGTT,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.glucose_targets.fasting,<5.3 mmol/L (95 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.glucose_targets.1h_postprandial,<7.8 mmol/L (140 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.glucose_targets.2h_postprandial,<6.7 mmol/L (120 mg/dL),entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.glucose_targets.bedtime,5.0-6.7 mmol/L,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.medical_nutrition_therapy.caloric_intake,25-35 kcal/kg孕前体重/日,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.medical_nutrition_therapy.carbohydrate,复合碳水化合物，40-50%总热量,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.medical_nutrition_therapy.protein,20%总热量,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.medical_nutrition_therapy.fat,25-30%总热量,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.medical_nutrition_therapy.meal_distribution,三大餐+2-3次加餐,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.physical_activity.recommendation,中等强度有氧运动,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.physical_activity.duration,30分钟/日，每周至少5天,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.physical_activity.types,快走; 游泳; 孕妇瑜伽,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.lifestyle_intervention.physical_activity.contraindications,妊娠并发症时禁止,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.insulin_therapy.indications,生活方式干预1-2周血糖不达标; 空腹血糖>5.8 mmol/L; 餐后2小时血糖>6.7 mmol/L,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.insulin_therapy.preferred_insulin,中效或长效胰岛素+速效胰岛素,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.insulin_therapy.regimens,每日2次预混胰岛素; 基础-餐时胰岛素方案,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.insulin_therapy.dosage,0.7-1.0 U/kg孕前体重/日起始,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.oral_medications.metformin,部分指南允许使用，需权衡利弊,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.oral_medications.sulfonylureas,格列本脲，二线选择,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,management.pharmacological_treatment.oral_medications.contraindicated,其他降糖药物孕期禁用,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,maternal_complications.pregnancy_complications,妊娠期高血压疾病; 羊水过多; 早产; 胎膜早破; 泌尿系感染,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,maternal_complications.delivery_complications,巨大儿导致难产; 肩难产; 产伤; 剖宫产率增加,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,maternal_complications.long_term_risks,产后2型糖尿病风险增加7倍; 心血管疾病风险增加; 代谢综合征; 再次妊娠GDM复发率30-70%,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,fetal_neonatal_complications.macrosomia.definition,出生体重≥4000g,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,fetal_neonatal_complications.macrosomia.mechanism,胎儿高胰岛素血症促进生长,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,fetal_neonatal_complications.macrosomia.complications,肩难产; 产伤; 剖宫产,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,fetal_neonatal_complications.neonatal_complications,新生儿低血糖; 新生儿呼吸窘迫综合征; 新生儿高胆红素血症; 新生儿低钙血症; 新生儿红细胞增多症,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,fetal_neonatal_complications.long_term_offspring_risks,儿童期肥胖风险增加; 青春期代谢综合征; 成年期2型糖尿病风险增加,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.timing.spontaneous_labor,血糖控制良好可等待自然分娩,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.timing.induction,孕39-40周考虑引产,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.timing.cesarean_section,血糖控制不良或胎儿过大,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.peripartum_glucose_management.labor_monitoring,每1-2小时监测血糖,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.peripartum_glucose_management.target_range,4.0-7.0 mmol/L,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,delivery_management.peripartum_glucose_management.insulin_adjustment,根据血糖调整胰岛素剂量,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.immediate_postpartum.insulin_discontinuation,产后立即停用胰岛素,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.immediate_postpartum.glucose_monitoring,监测血糖变化,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.immediate_postpartum.breastfeeding,鼓励母乳喂养,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.long_term_follow_up.diabetes_screening.timing,产后6-12周,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.long_term_follow_up.diabetes_screening.method,75g OGTT或FPG,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.long_term_follow_up.diabetes_screening.frequency,每1-3年筛查一次,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.long_term_follow_up.lifestyle_counseling,体重管理; 健康饮食; 规律运动; 戒烟限酒,entities_diabetes_entities.csv
entities.diabetes_entities,DM_002,妊娠期糖尿病,,disease,代谢性疾病,postpartum_follow_up.long_term_follow_up.family_planning,再次妊娠前咨询评估,entities_diabetes_entities.csv
entities.diabetes_entities,DM_003,成人起病的青年型糖尿病,,disease,遗传性糖尿病,genetic_classification.MODY2.characteristics,轻度持续性高血糖; 通常不需要药物治疗; 并发症风险低; 妊娠期需要监测,entities_diabetes_entities.csv
entities.diabetes_entities,DM_003,成人起病的青年型糖尿病,,disease,遗传性糖尿病,treatment.MODY2_treatment.pregnancy,妊娠期可能需要胰岛素,entities_diabetes_entities.csv
entities.diabetes_entities,DM_005,继发性糖尿病,,disease,继发性内分泌疾病,diagnosis.differential_diagnosis,1型糖尿病; 2型糖尿病; MODY; 妊娠糖尿病,entities_diabetes_entities.csv
entities.diabetes_medications,DM_MED_001,二甲双胍,,medication,双胍类降糖药,indications.additional,糖尿病前期（部分指南推荐）; PCOS相关胰岛素抵抗; 妊娠糖尿病（部分地区）,entities_diabetes_medications.csv
entities.diabetes_medications,DM_MED_006,胰岛素,,medication,胰岛素及类似物,indications.relative,2型糖尿病多种口服药物失效; 妊娠糖尿病; 急性应激状态; 严重感染,entities_diabetes_medications.csv
entities.diabetes_technology_devices,DM_TECH_001,连续血糖监测系统,,medical_device,血糖监测技术,indications,1型糖尿病患者; 胰岛素治疗的2型糖尿病; 妊娠糖尿病; 频发低血糖患者; 无症状低血糖患者,entities_diabetes_technology_devices.csv
entities.gonadal_entities,GON_001,多囊卵巢综合征,,disease,性腺疾病,clinical_manifestations.reproductive_features,月经稀发或闭经; 不孕; 流产率增加,entities_gonadal_entities.csv
entities.gonadal_entities,GON_001,多囊卵巢综合征,,disease,性腺疾病,treatment_strategies.pharmacological_therapy.reproductive_management.ovulation_induction.clomiphene.success_rate,排卵率70-80%，妊娠率35-40%,entities_gonadal_entities.csv
entities.gonadal_entities,GON_001,多囊卵巢综合征,,disease,性腺疾病,treatment_strategies.pharmacological_therapy.reproductive_management.ovulation_induction.letrozole.advantages,妊娠率更高，多胎率低,entities_gonadal_entities.csv
entities.gonadal_entities,GON_001,多囊卵巢综合征,,disease,性腺疾病,treatment_strategies.pharmacological_therapy.hyperandrogenism_management.antiandrogens,螺内酯 25-200mg/day; 醋酸环丙孕酮; 氟他胺,entities_gonadal_entities.csv
entities.gonadal_entities,GON_001,多囊卵巢综合征,,disease,性腺疾病,complications.reproductive,不孕症(70-80%); 妊娠糖尿病风险增加; 妊娠高血压风险增加; 流产率增加; 子宫内膜癌风险增加,entities_gonadal_entities.csv
entities.gonadal_entities,GON_003,女性性腺功能减退症,,disease,性腺疾病,clinical_manifestations.reproductive_symptoms,闭经或月经稀发; 不孕; 性欲减退; 阴道干燥,entities_gonadal_entities.csv
entities.gonadal_entities,GON_003,女性性腺功能减退症,,disease,性腺疾病,diagnostic_evaluation.additional_tests,妊娠试验; 泌乳素; TSH; 雄激素谱; 核型分析(早发者),entities_gonadal_entities.csv
entities.gonadal_entities,GON_005,Turner综合征,,disease,性腺疾病,clinical_features.gonadal_dysgenesis.infertility,不孕,entities_gonadal_entities.csv
entities.gonadal_entities,GON_005,Turner综合征,,disease,性腺疾病,management.fertility_considerations.spontaneous_pregnancy,5-10%可能性（镶嵌型）,entities_gonadal_entities.csv
entities.gonadal_entities,GON_005,Turner综合征,,disease,性腺疾病,management.fertility_considerations.pregnancy_risks,心血管并发症风险高,entities_gonadal_entities.csv
entities.gonadal_entities,GON_006,Kallmann综合征,,disease,性腺疾病,clinical_manifestations.reproductive_dysfunction.females.infertility,不孕,entities_gonadal_entities.csv
entities.gonadal_entities,GON_006,Kallmann综合征,,disease,性腺疾病,treatment.pubertal_induction.females.progestogen,子宫发育后添加孕激素,entities_gonadal_entities.csv
entities.gonadal_entities,GON_006,Kallmann综合征,,disease,性腺疾病,treatment.maintenance_therapy.females,雌孕激素替代治疗,entities_gonadal_entities.csv
entities.pituitary_entities,PIT_002,泌乳素瘤,,disease,垂体疾病,clinical_manifestations.hyperprolactinemia_effects.women,月经紊乱/闭经; 不孕; 溢乳; 性欲减退; 骨质疏松,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_002,泌乳素瘤,,disease,垂体疾病,diagnostic_workup.differential_diagnosis.physiological,妊娠; 哺乳; 应激; 睡眠,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_002,泌乳素瘤,,disease,垂体疾病,treatment_strategies.medical_therapy.dopamine_agonists.bromocriptine.pregnancy,妊娠期首选,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_005,垂体功能减退症,,disease,垂体疾病,hormonal_deficiencies.gonadotropin_deficiency.females.symptoms,闭经; 不孕; 潮热; 骨质疏松,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_005,垂体功能减退症,,disease,垂体疾病,treatment.hormone_replacement.sex_hormones.females,雌孕激素替代治疗,entities_pituitary_entities.csv
entities.pituitary_entities,PIT_006,垂体卒中,,disease,垂体疾病,predisposing_factors.triggering_events,高血压; 抗凝治疗; 妊娠分娩; 大手术; 糖尿病; 头部外伤,entities_pituitary_entities.csv
entities.thyroid_entities,THY_001,甲状腺功能亢进症,,disease,甲状腺疾病,clinical_manifestations.reproductive_symptoms,月经紊乱; 性功能减退; 不孕不育,entities_thyroid_entities.csv
entities.thyroid_entities,THY_001,甲状腺功能亢进症,,disease,甲状腺疾病,treatment_options.antithyroid_drugs.propylthiouracil.indications,妊娠期首选; 甲状腺危象; 甲巯咪唑过敏,entities_thyroid_entities.csv
entities.thyroid_entities,THY_001,甲状腺功能亢进症,,disease,甲状腺疾病,treatment_options.radioactive_iodine.contraindications,妊娠; 哺乳; 严重眼病,entities_thyroid_entities.csv
entities.thyroid_entities,THY_001,甲状腺功能亢进症,,disease,甲状腺疾病,treatment_options.surgical_therapy.indications,大甲状腺肿; 疑恶变; 妊娠期药物禁忌,entities_thyroid_entities.csv
entities.thyroid_entities,THY_002,甲状腺功能减退症,,disease,甲状腺疾病,clinical_manifestations.reproductive_symptoms,月经过多; 不孕; 性欲减退,entities_thyroid_entities.csv
entities.thyroid_entities,THY_002,甲状腺功能减退症,,disease,甲状腺疾病,treatment_protocols.levothyroxine_therapy.monitoring.pregnancy,每4-6周监测,entities_thyroid_entities.csv
entities.thyroid_entities,THY_002,甲状腺功能减退症,,disease,甲状腺疾病,treatment_protocols.levothyroxine_therapy.special_considerations.pregnancy.dose_increase,30-50%,entities_thyroid_entities.csv
entities.thyroid_entities,THY_002,甲状腺功能减退症,,disease,甲状腺疾病,treatment_protocols.levothyroxine_therapy.special_considerations.pregnancy.target_TSH,<2.5 mIU/L,entities_thyroid_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,clinical_manifestations.reproductive_features.infertility.anovulatory,排卵性不孕,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,clinical_manifestations.reproductive_features.infertility.prevalence,75%不孕症患者,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.pharmacological_treatment.menstrual_regulation.progestins.medroxyprogesterone,醋酸甲羟孕酮,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.pharmacological_treatment.hyperandrogenism_treatment.anti_androgens.cyproterone_acetate.dose,醋酸环丙孕酮 25-100mg/日,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.fertility_treatment.ovulation_induction.letrozole.advantages,较少多胎妊娠,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,long_term_complications.reproductive.infertility,排卵障碍导致不孕,female_endocrine_entities.csv
female_endocrine_entities,FEM_001,多囊卵巢综合征,,reproductive_endocrine_disorder,female_endocrine_disease,long_term_complications.reproductive.pregnancy_complications,妊娠期糖尿病; 妊娠期高血压; 早产; 胎儿宫内生长受限,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.hormone_therapy.systemic_ht.regimens.continuous_combined.composition,雌激素+孕激素每日,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.hormone_therapy.systemic_ht.regimens.cyclical.composition,雌激素连续+孕激素周期性,female_endocrine_entities.csv
female_endocrine_entities,FEM_002,绝经期综合征,,reproductive_endocrine_disorder,female_endocrine_disease,treatment.hormone_therapy.systemic_ht.preparations.oral.progestins,地屈孕酮; 微粒化黄体酮,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,name_en,Gestational Diabetes Mellitus (GDM),female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,description,妊娠期首次发现或发病的糖代谢异常,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,icd_10,O24.4,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,epidemiology.global_prevalence,1-14%(因诊断标准而异),female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,epidemiology.china_prevalence,14.8%(2019年数据),female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,epidemiology.increasing_trend,患病率逐年上升,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,epidemiology.risk_factors_prevalence,高龄妊娠、肥胖增加,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.pregnancy_insulin_resistance.mechanism,胎盘激素导致胰岛素抵抗,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.pregnancy_insulin_resistance.hormones,人胎盘生长激素; 皮质醇; 胎盘催乳素; 孕激素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.pregnancy_insulin_resistance.timeline,妊娠20周后明显,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.beta_cell_dysfunction.inadequate_compensation,β细胞代偿不足,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.beta_cell_dysfunction.genetic_predisposition,遗传易感性,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,pathophysiology.beta_cell_dysfunction.environmental_factors,肥胖、年龄等,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.maternal_factors.age,≥35岁,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.maternal_factors.obesity,孕前BMI≥25kg/m²,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.maternal_factors.family_history,糖尿病家族史,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.maternal_factors.ethnicity,高危种族,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.obstetric_history.previous_gdm,既往GDM史,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.obstetric_history.macrosomia,既往巨大儿分娩史,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.obstetric_history.stillbirth,死胎史,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.obstetric_history.polyhydramnios,羊水过多史,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.medical_history.pcos,多囊卵巢综合征,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.medical_history.hypertension,高血压,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,risk_factors.medical_history.previous_igt,既往糖耐量异常,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.screening_timing.universal_screening,24-28孕周,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.screening_timing.early_screening,高危因素者孕早期,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.screening_timing.method,75g OGTT,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.iadpsg_2010.fasting,≥5.1mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.iadpsg_2010.1h_post_load,≥10.0mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.iadpsg_2010.2h_post_load,≥8.5mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.iadpsg_2010.diagnosis,任一时间点异常即诊断,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.who_2013,采用IADPSG标准,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.diagnostic_criteria.china_2014,基本采用IADPSG标准,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.differential_diagnosis.overt_diabetes.criteria,空腹血糖≥7.0mmol/L; 随机血糖≥11.1mmol/L; HbA1c≥6.5%,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,diagnosis.differential_diagnosis.overt_diabetes.timing,妊娠期任何时间,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.maternal_symptoms.often_asymptomatic,多数无症状,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.maternal_symptoms.classic_symptoms,多饮、多尿; 疲劳; 反复感染,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.fetal_complications.macrosomia.definition,出生体重≥4000g,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.fetal_complications.macrosomia.mechanism,胎儿高胰岛素血症,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.fetal_complications.macrosomia.complications,肩难产; 产伤,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,clinical_manifestations.fetal_complications.neonatal_complications,新生儿低血糖; 呼吸窘迫综合征; 高胆红素血症; 低钙血症; 红细胞增多症,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.caloric_intake.normal_weight,30kcal/kg/日,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.caloric_intake.overweight,25kcal/kg/日,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.caloric_intake.obese,12-14kcal/kg/日,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.macronutrient_distribution.carbohydrate,40-50%,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.macronutrient_distribution.protein,20-25%,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.macronutrient_distribution.fat,25-30%,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.meal_planning.frequency,少量多餐,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.meal_planning.timing,规律进餐时间,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.nutritional_therapy.meal_planning.complex_carbs,复合碳水化合物为主,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.exercise_therapy.type,低强度有氧运动,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.exercise_therapy.duration,30分钟/次，每周5次,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.exercise_therapy.contraindications,前置胎盘; 早产史; 妊娠期高血压,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.glucose_monitoring.frequency,每日4-7次,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.glucose_monitoring.timing,空腹; 三餐后2小时; 必要时餐后1小时,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.glucose_monitoring.targets.fasting,<5.3mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.glucose_monitoring.targets.1h_postprandial,<7.8mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.glucose_monitoring.targets.2h_postprandial,<6.7mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.indications,饮食运动治疗2周后血糖不达标; 空腹血糖≥5.3mmol/L; 餐后血糖反复超标,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.insulin_types.rapid_acting,门冬胰岛素、赖脯胰岛素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.insulin_types.intermediate,NPH胰岛素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.insulin_types.long_acting,地特米胰岛素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.regimens.basal_bolus,基础-餐时胰岛素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.regimens.bid_nph,NPH胰岛素每日两次,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.insulin_therapy.regimens.adjustment,根据血糖调整剂量,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.oral_agents.metformin.safety,FDA妊娠期B类,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.oral_agents.metformin.indications,部分国家指南推荐,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.oral_agents.metformin.monitoring,胎儿生长发育,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.oral_agents.glyburide.use,部分地区使用,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,management.oral_agents.glyburide.concerns,胎盘通透性,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.maternal_monitoring.glucose_control,血糖日记记录,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.maternal_monitoring.weight_gain,孕期体重管理,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.maternal_monitoring.blood_pressure,血压监测,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.maternal_monitoring.ketones,尿酮体检查,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.growth_assessment.ultrasound,每4周超声检查,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.growth_assessment.biometry,胎儿生物测量,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.growth_assessment.amniotic_fluid,羊水量评估,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.fetal_wellbeing.nst,胎心监护,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.fetal_wellbeing.bpp,生物物理评分,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,monitoring.fetal_monitoring.fetal_wellbeing.timing,32-34周开始,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.timing.well_controlled,39-40周,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.timing.poor_control,考虑提前终止妊娠,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.timing.macrosomia,38-39周,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.mode_of_delivery.vaginal_delivery,首选自然分娩,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.mode_of_delivery.cesarean_indications,估计胎重≥4500g; 既往肩难产史; 产科指征,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.intrapartum_management.glucose_monitoring,每1-2小时监测血糖,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.intrapartum_management.insulin_adjustment,根据血糖调整胰岛素,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,delivery_management.intrapartum_management.target,血糖4.0-7.0mmol/L,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.immediate_postpartum.insulin_discontinuation,胰岛素立即停用,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.immediate_postpartum.glucose_monitoring,监测血糖变化,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.immediate_postpartum.breastfeeding,鼓励母乳喂养,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.follow_up_screening.timing,产后6-12周,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.follow_up_screening.method,75g OGTT,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.follow_up_screening.interpretation,评估糖代谢状态,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.long_term_follow_up.annual_screening,每年糖尿病筛查,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.long_term_follow_up.lifestyle_counseling,生活方式指导,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,postpartum_care.long_term_follow_up.preconception_counseling,再次妊娠前咨询,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,complications.maternal_complications.pregnancy,妊娠期高血压; 子痫前期; 羊水过多; 感染风险增加,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,complications.maternal_complications.delivery,剖宫产率增加; 产后出血; 产道损伤,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,complications.fetal_neonatal_complications.immediate,新生儿低血糖; 呼吸窘迫; 高胆红素血症; 低钙血症,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,complications.fetal_neonatal_complications.long_term,儿童期肥胖; 青春期糖尿病风险; 代谢综合征,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.maternal_outcomes.diabetes_risk,50-70%发展为2型糖尿病,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.maternal_outcomes.cardiovascular_risk,心血管疾病风险增加,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.maternal_outcomes.recurrence_risk,再次妊娠复发率30-84%,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.offspring_outcomes.obesity_risk,儿童肥胖风险增加,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.offspring_outcomes.diabetes_risk,青春期糖尿病风险增加,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,long_term_outcomes.offspring_outcomes.metabolic_programming,代谢编程效应,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prevention.primary_prevention.preconception,体重管理; 健康饮食; 规律运动; 叶酸补充,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prevention.secondary_prevention.lifestyle_interventions,饮食指导; 运动计划; 体重控制; 定期随访,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prognosis.immediate_outcomes,良好的血糖控制可改善母儿结局,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prognosis.long_term_health,需要终生糖尿病风险管理,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prognosis.quality_of_life,适当管理下可维持正常生活,female_endocrine_entities.csv
female_endocrine_entities,FEM_003,妊娠期糖尿病,,pregnancy_related_disorder,female_endocrine_disease,prognosis.family_planning,可安全进行再次妊娠,female_endocrine_entities.csv
glucose_management_entities,CGM_001,连续血糖监测系统,,monitoring_technology,血糖监测技术,clinical_applications.diabetes_management.type2_diabetes.适用人群,胰岛素治疗患者; 多次药物调整患者; 妊娠糖尿病患者; 糖尿病前期高危人群,glucose_management_entities.csv
glucose_management_entities,CGM_001,连续血糖监测系统,,monitoring_technology,血糖监测技术,clinical_applications.gestational_diabetes.monitoring_protocol.wearing_duration,孕24-28周开始，持续至分娩,glucose_management_entities.csv
glucose_management_entities,MEAL_001,餐后血糖管理,,clinical_management,血糖管理策略,assessment_criteria.target_ranges.pregnancy,< 6.7 mmol/L (2小时),glucose_management_entities.csv
glucose_management_entities,EXERCISE_001,运动血糖管理,,clinical_management,血糖管理策略,special_considerations.pregnancy.gestational_diabetes,妊娠糖尿病运动管理,glucose_management_entities.csv
glucose_management_entities,EXERCISE_001,运动血糖管理,,clinical_management,血糖管理策略,special_considerations.pregnancy.safety_parameters,母儿安全血糖范围,glucose_management_entities.csv
glucose_management_entities,EXERCISE_001,运动血糖管理,,clinical_management,血糖管理策略,special_considerations.pregnancy.activity_modifications,孕期运动类型调整,glucose_management_entities.csv
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,description,夫妇正常性生活未避孕12个月未能妊娠，男方因素导致的生育能力障碍,male_endocrine_entities.csv
male_endocrine_entities,MAL_003,男性不育症,,reproductive_disorder,male_endocrine_disease,prognosis.natural_conception,轻度异常患者可能自然受孕,male_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,epidemiology.high_risk_populations,老年人; 孕产妇; 婴幼儿; 室内工作者; 深色皮肤人群,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_001,维生素D缺乏症,,nutritional_disorder,nutrition_endocrine_disease,risk_factors.physiological,年龄增长; 深色皮肤; 肥胖; 妊娠哺乳期,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_002,碘缺乏病,,nutritional_disorder,nutrition_endocrine_disease,epidemiology.vulnerable_populations,孕产妇; 婴幼儿; 儿童青少年,nutrition_endocrine_entities.csv
nutrition_endocrine_entities,NUT_002,碘缺乏病,,nutritional_disorder,nutrition_endocrine_disease,pathophysiology.developmental_effects.brain_development,胎儿期和婴儿期关键,nutrition_endocrine_entities.csv
obesity_metabolic_entities,OBE_001,肥胖症,,metabolic_disorder,nutrition_metabolic_disease,treatment.pharmacological_treatment.selection_criteria.contraindications,妊娠、严重精神疾病,obesity_metabolic_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,treatment.gonadal_hormone.females.estrogen_progesterone,雌孕激素替代,parathyroid_calcium_entities.csv
parathyroid_calcium_entities,PTH_003,假性甲状旁腺功能减退症,,genetic_disorder,parathyroid_disease,treatment.gonadal_hormone.females.contraception,避孕需求评估,parathyroid_calcium_entities.csv
pediatric_endocrine_entities,PED_002,儿童甲状腺疾病,,endocrine_disorder,pediatric_endocrine_disease,treatment.hyperthyroidism_treatment.antithyroid_drugs.propylthiouracil.indication,妊娠、甲状腺危象,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_002,儿童甲状腺疾病,,endocrine_disorder,pediatric_endocrine_disease,treatment.hyperthyroidism_treatment.definitive_treatment.radioiodine.contraindications,妊娠、哺乳,pediatric_endocrine_entities.csv
pediatric_endocrine_entities,PED_004,儿童性早熟,,endocrine_disorder,pediatric_endocrine_disease,prognosis.reproductive_health.pregnancy_outcomes,正常妊娠结局,pediatric_endocrine_entities.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.pregnancy_complications.relationship_type,高风险,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,systemic_lupus_relationships.target_diseases.reproductive_endocrine.pregnancy_complications.complications,妊娠期糖尿病、甲状腺功能异常,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,disease_relationship_matrix,disease relationship matrix,,,,hyperuricemia_gout_relationships.target_diseases.diabetes_mellitus.gestational_diabetes.mechanism,妊娠期胰岛素抵抗影响尿酸代谢,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,target_diseases.pcos_metabolic_connections.thyroid_interactions.clinical_overlap,月经不调; 不孕; 代谢异常,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.insulin_resistance,妊娠期生理性胰岛素抵抗,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.thyroid_adaptations,hCG对甲状腺的刺激作用,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.adrenal_modifications,皮质醇和醛固酮分泌增加,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,fertility_endocrine_interactions.pregnancy_endocrine_changes.calcium_homeostasis,PTHrP分泌和钙代谢调节,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,reproductive_endocrine_relationships,reproductive endocrine relationships,,,,therapeutic_considerations.hormone_replacement_principles.pcos_management.antiandrogen_therapy,螺内酯、醋酸环丙孕酮,rheumatic_endocrine_relationships.csv
rheumatic_endocrine_relationships,clinical_decision_pathways,clinical decision pathways,,,,treatment_considerations.monitoring_protocols.pregnancy_management,妊娠期多种激素替代治疗管理,rheumatic_endocrine_relationships.csv
